Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
Not Confirmed
Not Confirmed
30 September-02 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Industry Trade Show
Not Confirmed
30 September-02 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
30 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/en/news-release/2024/09/30/2954940/0/en/European-Commission-approves-Yuvanci-Single-Tablet-Combination-Therapy-STCT-of-Macitentan-and-Tadalafil-for-Treatment-of-Patients-with-Pulmonary-Arterial-Hypertension-PAH.html
27 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/en/news-release/2024/09/27/2954710/0/en/CARVYKTI-ciltacabtagene-autoleucel-cilta-cel-is-the-first-cell-therapy-to-significantly-extend-overall-survival-versus-standard-therapies-for-patients-with-multiple-myeloma-as-earl.html
27 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/en/news-release/2024/09/27/2954470/0/en/TALVEY-talquetamab-and-DARZALEX-daratumumab-subcutaneous-SC-formulation-based-combination-shows-deep-and-durable-responses-in-patients-with-relapsed-or-refractory-multiple-myeloma.html
20 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/20/2949618/0/en/Dupixent-dupilumab-Recommended-for-EU-Approval-by-the-CHMP-to-Treat-Eosinophilic-Esophagitis-EoE-in-Children-as-Young-as-1-Year-Old.html
20 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/20/2949615/0/en/DARZALEX-daratumumab-based-quadruplet-regimen-receives-positive-CHMP-opinion-for-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma.html
16 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/15/2946278/0/en/New-data-from-TAR-200-Phase-2b-SunRISe-1-study-show-84-percent-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer.html
ABOUT THIS PAGE
Janssen-Cilag is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BORGO SAN MICHELE, ITALY bulk offered by Janssen-Cilag
LOOKING FOR A SUPPLIER?